Rheumatology 2000; 39: 1004-1008
© 2000 British Society for Rheumatology
Nitric oxide is a mediator of apoptosis in the rheumatoid joint
Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen AB25 2ZD, UK
Objective. To study the role of nitric oxide (NO) derived from the inducible nitric oxide synthase (iNOS) pathway in the induction of apoptosis in the rheumatoid joint.
Methods. Joint tissue was obtained from four rheumatoid arthritis (RA) patients, three osteoarthritis patients and two patients with a fractured neck of the femur (NOF#), and apoptotic cells were identified in cryosections using the TUNEL (terminal dUTP nick end labelling) assay. Expression of iNOS was determined using immunohistochemistry. NO synthesis and the effect of NOS inhibitors on apoptosis levels were studied in explant cultures of RA cartilage and synovium.
Results. Numbers of apoptotic cells were greatly increased in rheumatoid synovium and articular cartilage compared with NOF# and osteoarthritic synovium. Immunohistochemistry showed co-localization of iNOS staining and apoptosis in the synovial lining layer and articular cartilage. The NOS inhibitor L-NMMA (L-NG-monomethylarginine) strongly inhibited apoptosis in explant cultures of synovium and cartilage, and this was reversed by the NO donor S-nitroso-acetyl-penicillamine.
Conclusion. This study indicates that NO acts as a mediator of apoptosis in RA and suggests that NOS inhibitors reverse this process.
KEY WORDS: Rheumatoid arthritis, Cytokines, Nitric oxide, Apoptosis, Cartilage, Synovium
Correspondence to: S. H. Ralston.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S.-S. Nah, I.-Y. Choi, C. K. Lee, J. S. Oh, Y. G. Kim, H.-B. Moon, and B. Yoo Effects of advanced glycation end products on the expression of COX-2, PGE2 and NO in human osteoarthritic chondrocytes Rheumatology, April 1, 2008; 47(4): 425 - 431. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vazgiourakis, P. Sidiropoulos, G. Bertsias, E. Koutsounaki, E. Fragouli, A. Raptopoulou, H. Kritikos, D.T. Boumpas, and G.N. Goulielmos Association of the nitric oxide synthase (eNOS) gene polymorphism with increased risk for both lupus glomerulonephritis and rheumatoid arthritis in a single genetically homogeneous population Lupus, November 1, 2007; 16(11): 867 - 874. [Abstract] [PDF] |
||||
![]() |
M. A. Gonzalez-Gay, J. Llorca, E. Sanchez, M. A. Lopez-Nevot, M. M. Amoli, C. Garcia-Porrua, W. E. R. Ollier, and J. Martin Inducible but not endothelial nitric oxide synthase polymorphism is associated with susceptibility to rheumatoid arthritis in northwest Spain Rheumatology, September 1, 2004; 43(9): 1182 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
O Elkayam, I Yaron, I Shirazi, R Judovitch, D Caspi, and M Yaron Active leflunomide metabolite inhibits interleukin 1{beta}, tumour necrosis factor {alpha}, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures Ann Rheum Dis, May 1, 2003; 62(5): 440 - 443. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Ersoy, E Ozerol, O Baysal, I Temel, R S MacWalter, U Meral, and Z E Altay Serum nitrate and nitrite levels in patients with rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis Ann Rheum Dis, January 1, 2002; 61(1): 76 - 78. [Abstract] [Full Text] [PDF] |
||||


